The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence : Current Opinion in Rheumatology

Secondary Logo

Journal Logo

Advanced Search
Rheumatoid arthritis

The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence

Siddiqui, M Asif A

Author Information

Wolters Kluwer Health | Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

Correspondence to M. Asif A. Siddiqui, Wolters Kluwer Health, Adis, 41 Centorian Drive, Private Bag 65901, Mairangi, Bay, Auckland 1311, New Zealand E-mail: [email protected]

Current Opinion in Rheumatology 19(3):p 308-313, May 2007. | DOI: 10.1097/01.bor.0000265447.48722.04

Abstract

(1) Biologics have had a tremendous impact on the management of rheumatoid arthritis.

(2) Three new biologics have been approved or filed for approval for the treatment of rheumatoid arthritis in the last 2 years: abatacept, rituximab, and tocilizumab.

(3) The utility of the newer biologics against the background of existing, well established biologics (infliximab, etanercept, adalimumab, and anakinra) has not been evaluated systematically.

© 2007 Lippincott Williams & Wilkins, Inc.

Full Text Access for Subscribers:

Not a Subscriber?

Buy
Request Permissions

You can read the full text of this article if you:

Access through Ovid
-